NASDAQ$VERA
Vera Therapeutics Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.
Vera Therapeutics reported a net loss of $3.4 million, or a net loss per diluted share of $0.33, and cash and cash equivalents of $91.6 million.
- Initiated patient enrollment for the dose-ranging Phase 2b ORIGIN trial, evaluating atacicept in IgAN patients.
- Expanded the management team with the appointment of Sean Grant as Chief Financial Officer.
- Reported $91.6 million in cash and cash equivalents as of June 30, 2021, including net proceeds from the company’s initial public offering.
- Net loss was $3.4 million, or $0.33 per diluted share.
Headline financials
Revenue & EPS history
Vera · Revenue · Quarterly
$362K
Forward guidance
The press release contains forward-looking statements regarding the results of Vera’s Phase 2b ORIGIN trial.
Tailwinds
- statements regarding the results of Vera’s Phase 2b ORIGIN trial
- plans
- will
- anticipates
- goal
Headwinds
- risks and uncertainties associated with Vera’s business in general
- the impact of the COVID-19 pandemic
- the other risks described in Vera’s filings with the Securities and Exchange Commission.
- Actual results could differ materially from those anticipated
- involve assumptions that may never materialize or may prove to be incorrect
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2021
+0.2%
Avg return
Earnings day
+2.3%
Avg return
5 days after
+7.2%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+15.6%
Q1 2022
Best reaction
-13.5%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -2.0% | +0.3% | -11.8% | |
| Q4 2025 | +1.5% | -5.7% | -6.8% | |
| Q3 2025 | +4.6% | +23.3% | +86.3% | |
| Q1 2025 | -13.5% | -15.0% | +20.0% | |
| Q4 2024 | +1.3% | -0.7% | -22.1% | |
| Q3 2024 | +0.3% | +1.3% | +1.1% | |
| Q2 2024 | +0.9% | +6.5% | +4.3% | |
| Q1 2024 | -8.1% | -9.1% | -14.3% | |
| Q4 2023 | -1.3% | -5.2% | -12.5% | |
| Q3 2023 | +5.4% | +18.2% | +18.9% | |
| Q2 2023 | -0.1% | -4.3% | -0.1% | |
| Q1 2023 | -1.7% | +0.0% | +0.9% | |
| Q4 2022 | +4.4% | +6.3% | -14.2% | |
| Q3 2022 | -3.2% | -3.8% | -2.1% | |
| Q2 2022 | +7.8% | +20.6% | +11.4% | |
| Q1 2022 | +15.6% | +11.4% | -8.5% | |
| Q4 2021 | +10.2% | +11.2% | +5.2% | |
| Q3 2021 | -11.6% | -7.1% | -3.3% | |
| Q2 2021 | +0.3% | +11.6% | +80.6% | |
| Q1 2021 | -7.6% | -13.6% | +11.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro